Loss of Lung Function Slowed With Fluticasone Furoate Tx

Share this content:
In patients with moderate COPD and heightened cardiovascular risk, FF alone or in combination with VI appears to reduce the rate of FEV1 decline.
In patients with moderate COPD and heightened cardiovascular risk, FF alone or in combination with VI appears to reduce the rate of FEV1 decline.

HealthDay News — Regular use of fluticasone furoate (FF), either alone or in combination with vilanterol (VI), appears to reduce the rate of forced expiratory volume in one second (FEV1) decline in patients with moderate chronic obstructive pulmonary disease (COPD) and a high risk of cardiovascular disease, according to a study published online in the American Journal of Respiratory and Critical Care Medicine.

Peter MA Calverley, MB, ChB, from University of Liverpool in the United Kingdom, and colleagues conducted prespecified analysis of the key secondary outcome in the Study to Understand Mortality and MorbidITy (SUMMIT) to determine how inhaled corticosteroid FF (100 µg), the long-acting beta-agonist VI (25 µg), or the combination (FF/VI) modified the rate of decline in FEV1 versus placebo.

The researchers found that FF-containing regimes had lower rates of decline than placebo (P <.03), and FF/VI had lower rates of decline than VI alone (P <.005). The FEV1 decline was faster in current smokers, those with a lower body mass index, males, and patients with established cardiovascular disease.

"In patients with moderate COPD and heightened cardiovascular risk, FF alone or in combination with VI appears to reduce the rate of FEV1 decline," the authors write.

The study was funded by GlaxoSmithKline, which markets fluticasone furoate.

Reference

Calverley PMA, ANderson JA, Brook RD, et al. Fluticasone furoate, vilanterol and lung function decline in patients with moderate COPD and heightened cardiovascular risk [published online July 24, 2017]. Am J Respir Crit Care Med. doi:10.1164/rccm.201610-2086OC


Sign Up for Free e-newsletters